Decreasing Depression & Anxiety Levels
A descriptive study that compares the depression and anxiety levels of patients before and after using Wellnite
19% of adults are estimated to have had an anxiety disorder in the past year.
Nearly 8% of adults in the US are suffering from depression.
Over half of individuals with depression report difficulty with completing daily activities.
A further 31% of adults are estimated to have had an anxiety disorder at some point in their lifetime.
The GAD-7 (anxiety) and PHQ-9 (depression disorders) are some of the gold standard techniques that are used to measure and classify these conditions.
The PHQ-9 is a nine-item screening questionnaire used to measure depression. The questionnaire has a maximum score of 27, with higher scores indicating the severity of depression.
The GAD-7 is a screening questionnaire for generalized anxiety disorder. The questionnaire has a maximum score of 21 with higher scores indicating the severity of anxiety.
Anxiety & Depression Disorders:
There are different types of anxiety and depression disorders, including: generalized anxiety disorder, panic disorder, persistent depressive disorder, seasonal affective disorder, psychotic depression, postpartum depression, and various other phobia-related disorders.
Data-Driven Combination Therapy
We found that patients who used Wellnite's services lowered their GAD-7 and PHQ-9 scores overall. This descriptive analysis demonstrates that Wellnite is providing efficacious mental health services. This data will help us improve out pharmacological and non-pharmacological services to better tailor treatment to our users.
Read the full descriptive analysis here.
Upon enrollment, patients had an average PHQ-9 score of 16, indicating moderately severe depression.
For the GAD-7, the average score was 14, indicating severe anxiety
Chat Your Problems Away
Patients that used the chat based feature saw a 33% decrease in their depression score compared to those who did not.
Getting It Just Right:
Not all medications work the same for everyone.
Patients who changed medications with Wellnite saw a ~30% decrease in PHQ-9 and GAD-7 scores compared to those who did not.
Both average PHQ-9 and GAD-7 scores decreased during Wellnite use.
At enrollment, the cohort’s depression and anxiety were classified as moderately severe and moderate, respectively, according to initial average PHQ-9 and GAD-7 scores. At the end of the follow-up period, average depression and anxiety scores were classified as mild.
While the PHQ-9 and GAD-7 are not diagnostic tests, reduction in scores through the use of Wellnite shows promise in our service’s ability to ameliorate depressive and anxiety symptoms.